HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes

Cancer Research

Volumn 71, Issue 2, 2011, Pages 349-359

  Wu, Jingjing ^a,b   Liu, Zhaojian ^b   Shao, Changshun ^a,c   Gong, Yaoqin ^a   Hernando, Eva ^d   Lee, Peng ^d   Narita, Masashi ^e   Muller, William ^b   Liu, Jinsong ^f   Wei, Jian Jun ^b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; LUMICAN; MICRORNA; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE; GENE CONTROL; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; ONCOGENE; OVARY CANCER; PAPILLARY CARCINOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; SURFACE PROPERTY; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CASE-CONTROL STUDIES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CHONDROITIN SULFATE PROTEOGLYCANS; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; HMGA2 PROTEIN; HUMANS; KERATAN SULFATE; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 78751509847     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2550     Document Type: Article

References (37)

1. Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, Thomssen C, et al. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 2008;14:89-96.
2. Salani R, Kurman RJ, Giuntoli R II, Gardner G, Bristow R, Wang TL, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer 2008;18:487-91.
3. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009;3:138-50.
4. Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, et al. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One 2009;4:e8404.
5. Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 2009;4:e8534.
6. Park SM, Shell S, Radjabi AR, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007;6:2585-90.
7. Mahajan A, Liu Z, Gellert L, Zhou X, Yang G, Lee P, et al. HMGA2:a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol 2010;23:673-81.
8. Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P, et al. HMGA2:a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 2010;34:18-26.
9. Reeves R. Structure and function of the HMGI(Y) family of architectural transcription factors. Environ Health Perspect 2000;108 Suppl 5: 803-9.
10. Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P, et al. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 2008;6:663-73.
11. Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 2009;22:43-9.
12. Tzatsos A, Bardeesy N. Ink4a/Arf regulation by let-7b and Hmga2: a genetic pathway governing stem cell aging. Cell Stem Cell 2008; 3:469-70.
13. Nishino J, Kim I, Chada K, Morrison SJ. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 2008;135:227-39.
14. Li AY, Boo LM, Wang SY, Lin HH, Wang CC, Yen Y, et al. Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res 2009;69:5699-706.
15. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007;104:11400-5.
16. Thuault S, Tan EJ, Peinado H,CanoA,HeldinCH,Moustakas A.HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial- to-mesenchymal transition. J Biol Chem 2008;283:33437-46.
17. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009;174:854-68.
18. Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 2008;123:348-56.
19. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63.
20. Narita M, Narita M, Krizhanovsky V, Nuñez S, Chicas A, Hearn SA, et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006;126:503-14.
21. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009;16:23-9.
22. Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, et al. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer 2009;19:641-7.
23. De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Martinez Hoyos J, et al. Regulation of microRNA expression by HMGA1 proteins. Oncogene 2009;28:1432-42.
24. Dahiya N, Morin PJ. MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 2010;17:F77-89.
25. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459-71.
26. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315:1576-9.
27. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, et al. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 2008;6:743-50.
28. Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer 2008;44:1015-21.
29. Fabjani G, Tong D, Wolf A, Roka S, Leodolter S, Hoecker P, et al. HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep 2005;14:737-41.
30. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
31. Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O'Briant KC, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-toepithelial transition. Gynecol Oncol 2010;116:117-25.
32. Luna C, Li G, Qiu J, Epstein DL, Gonzalez P. Role of miR-29b on the regulation of the extracellular matrix in human trabecular meshwork cells under chronic oxidative stress. Mol Vis 2009; 15:2488-97.
33. Blochberger TC, Cornuet PK, Hassell JR. Isolation and partial characterization of lumican and decorin from adult chicken corneas. A keratan sulfate-containing isoform of decorin is developmentally regulated. J Biol Chem 1992;267:20613-9.
34. Saika S, Miyamoto T, Tanaka S, Tanaka T, Ishida I, Ohnishi Y, et al. Response of lens epithelial cells to injury: role of lumican in epithelialmesenchymal transition. Invest Ophthalmol Vis Sci 2003;44:2094-102.
35. Nikitovic D, Berdiaki A, Zafiropoulos A, et al. Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J 2008;275:350-61.
36. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003;9:207-14.
37. Law AY, Wong CK. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res 2010;316:3425-34.